Rapport Therapeutics

Rapport Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2022 and headquartered in Boston, Massachusetts, with additional operations in San Diego, California. The company is dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders. Rapport's prop... rietary RAP technology platform targets receptor-associated proteins (RAPs) to precisely modulate disease-driving neurocircuits, aiming to overcome the limitations of existing neuromedicines that act broadly throughout the nervous system. The company's lead program, RAP-219, is an investigational small molecule being developed for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additional discovery-stage programs target chronic pain and hearing disorders. Rapport was conceptualized through a partnership between Third Rock Ventures and Johnson & Johnson Innovation and completed its initial public offering in 2024. The company trades on the NASDAQ under the ticker symbol RAPP.Read More